This document discusses Dart Diagnostics, a startup developing a modular plug-and-play element for signal multiplication in real-time detection, valued at $14.7 billion in 2015. The founders have extensive experience and awards in areas like biophysics, biochemistry, and nanomedicine. Dart has obtained seed funding and is validating its technology by comparing it to commercial kits for food safety and clinical diagnostics. Upon further validation and patenting, the company aims to expand into microfluidic devices, seek additional funding, and pursue partnerships, licensing agreements, or acquisition by a pharmaceutical/diagnostics firm.

1. dart.diagnostics@gmail.com

4. OUR MODULAR PLUG-AND-PLAY ELEMENT
SIGNAL MULTIPLICATION

5. R E A L - T I M E D E T E C T I O N

6. GROWTH RATE: 5.11%
VALUED AT $14.7 BILLION IN 2015
global immunoassay instruments/analyzers market
Source:
http://www.grandviewresearch.com/industry-analysis/immunoassay-instruments-analyzers-market

7. Disease diagnosis/paper strip
DNA tests on demand
Biomolecular determination
quick test for multidrug-resistant organisms
Pathogen Screening Device
Molecular Diagnostics
Blood analysis system
Automated POC diagnostic system
Testing of blood cultures

8. Biophysics Biochemistry Nanomedicine Biosensing
Ivo C. Martins Ana S. Martins Patrícia M. Carvalho
Genetics
Virology
Biotechnology
Nanotechnology
Microbiology
Bioengineering

9. • Boehringer Ingelheim Fonds Ph.D. Grant
• Marie Curie Post-Doc Grant
• Life Sciences Frontier Research Prize, Calouste
Gulbenkian Foundation, Lisbon, Portugal
• FCT Investigator independent researcher
• Hans Neurath Outstanding Promise Award, Hans
Neurath Foundation
• International Patent Office, Nr WO/2012/159187 (priority
date: 26/05/2011)
• International Patent Office, Nr WO/2008/028939 (priority:
13/03/2008; 04/05/2007; 08/09/2006)
• FCT Research Fellowship
• FCT Doctoral Grant
• Selected speaker at 5th International Iberian
Biophysics Congress
• Competitive EMBO funding for a collaboration in
Singapore (A*STAR Agency)
• FCT Research Fellowship
• FCT Doctoral Grant
• NanoPT (Nanotechnology) Travel Grant
• Twice awarded the Beca a la Excelencia Formativa
de la Fundación Grupo Siro
JOINTLY CONCLUDED THE 2016 PROGRAM

10. FCT FUNDED PROJECT (144.010 €)
- Early development-
- Team formation -
- Obtaining DART reagent -
CXC SEED CAPITAL (100.000 €) LICENSING AGREEMENT WITH iMM
PHYSICAL ADDRESS AT TECLABS
- Private Office Space -
- Private Laboratory Space -
- General Lab Equipment -

11. IMPROVING IP
IMPROVING TOP SELLING KITS
- Challenge companies to buy from us -
- Sub-licensing of application -
EXPAND INTO MICROFLUIDIC DEVICES
- Ongoing -
- If desired, with automation included -

12. 1 2 3 4 5 6
FINAL
VALIDATIONSETUP
BUSINESS
EXPANSION
1
1 8 9 10 11 127
Validation with wide range of targets
GROUP 1
Market ResearchTroubleshooting
GROUP 2
compare DART
with other kits for
the food industry Benchmark DART against 1 commercial kit
Patent strategy validation
PATENT
SUBMISSION
GROUP 3
clinical diagnostics
& BD
DART against 2 more kits
BD & second round of funding
obtain data for a wide
patent & establish a
platform to develop
and test kits

13. PARTNER CURRENT MINIMUM DILUTION MAXIMUM DILUTION
Ivo Martins 51,9% 49,4% 46,8%
Patrícia Carvalho 24,0% 22,8% 21,6%
Ana Martins 24,0% 22,8% 21,6%
PROMOTORS 99,9% 95,0% 90,0%
FCR Caixa TTA Ventures 0,1% 5,0% 10,0%

14. PHASE I (100.000 €)
- CxC venture funding -
PHASE II (500.000 €)
- Invited to Lisbon Investment Summit -
- Invited to Boehringer Ingelheim alumni reunion -
- CxC and other national investors -
Setup & Equipment
Facilities
Reagents
One full-time position
Accounting & Legal
Patent initial costs
Final IP Costs
Certiification
Sales Costs
Scale-up
Personnel
Automation

15. SALES-BASED MODEL POSSIBLE IPO
ACQUISITION BY A PHARMA/DIAGNOSTICS COMPANY
LICENSING OF ALL IP APPLICATIONS

16. SAVE TIME
SAVE MONEY
P L U G - A N D - P L A Y T E C H N O L O G Y
- applicable to any immunoassay -
NEW GENERATION TEST KITS
ULTRA SENSITIVE DIAGNOSTICS

17. dart.diagnostics@gmail.com